Cartesian Therapeutics News

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today

GlobeNewswireMay 13 16:30 ET

Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ...

Yahoo FinanceMay 10 15:12 ET

Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion

TipRanksMay 10 01:31 ET

Express News | HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $54 Price Target

BenzingaMay 9 15:24 ET

Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham

Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham

Dow JonesMay 8 11:50 ET

Express News | Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

BenzingaMay 8 11:40 ET

Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)

TipRanksMay 8 11:32 ET

Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026

Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026

BenzingaMay 8 07:22 ET

Cartesian Therapeutics Q1 2024 GAAP EPS $(10.50) May Not Be Comparable To $(0.89) Estimate, Sales $5.840M May Not Be Comparable To $1.250M Estimate

Cartesian Therapeutics Q1 2024 GAAP EPS $(10.50) May Not Be Comparable To $(0.89) Estimate, Sales $5.840M May Not Be Comparable To $1.250M Estimate

BenzingaMay 8 07:22 ET

Cartesian Therapeutics Provides Business Updates at Industry Events

TipRanksMay 8 07:12 ET

Express News | Cartesian Therapeutics Inc - Cash, Cash Equivalents, and Restricted Expected to Support Planned Operations Into 2H 2026

ReutersMay 8 07:11 ET

Cartesian Therapeutics | 10-Q: Quarterly report

Futu NewsMay 8 07:08 ET · Announcements

Cartesian Therapeutics 1Q Loss/Shr $10.50 >RNAC

Cartesian Therapeutics 1Q Loss/Shr $10.50 >RNAC

Dow JonesMay 8 07:07 ET

Express News | Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

ReutersMay 8 07:00 ET

Press Release: Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Topline data from Phase 2b trial of Descartes-08, the Company's potential first-in-class mRNA CAR-T ce

Dow JonesMay 8 07:00 ET

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement

BusinesswireMay 6 16:15 ET

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.Nucor reported quarterly earnings of $3.46 per s

BenzingaApr 23 13:53 ET

Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 23 12:32 ET

Express News | HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Adjusts Price Target To $54

Moomoo 24/7Apr 23 12:26 ET

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday.Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply during Tuesday's session following upbeat quarterly result

BenzingaApr 23 10:50 ET